Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma - PubMed
6 hours ago
- #Rituximab Maintenance
- #Mantle Cell Lymphoma
- #Survival Benefit
- The benefit of rituximab maintenance after first-line bendamustine-rituximab (BR) in mantle cell lymphoma (MCL) patients was studied.
- A large retrospective study across 27 US and Canadian academic centers involved 911 patients treated with 1L BR between 2010 and 2020.
- 703 patients had an objective response and no disease progression at the 3-month post-BR landmark; 394 received rituximab maintenance, while 309 did not.
- Rituximab maintenance significantly improved event-free survival (EFS) and overall survival (OS) compared to no maintenance (median EFS: 49.9 vs. 29.7 months; median OS: 109.5 vs. 74.2 months).
- Survival benefits were consistent across most subgroups, particularly in patients achieving complete response to 1L BR.
- The study supports the use of rituximab maintenance in clinical trial design and routine practice for MCL patients.